Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Progesterone Induced Blocking Factor Expression Levels in Endometrial Cancer Cells.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02852954
Recruitment Status : Completed
First Posted : August 2, 2016
Last Update Posted : August 18, 2017
Sponsor:
Information provided by (Responsible Party):
Erdem Sahin, Kayseri Education and Research Hospital

Brief Summary:
Immune system suppression effect of Progesterone Induced Blocking Factor(PIBF), it could be questionable whether tumor cells express PIBF for escape of immune system. There are some studies in the literature that evaluate PIBF expression of different malign cells (e.g. glioblastoma multiforme as a malign central nerve system, leukemia, astrocytoma as a primary brain tumor, lung cancer and chorionic carcinoma). According to previous studies PIBF has been used as an anti-tumor immune suppressor by tumor cells. There is no data about the PIBF expression of endometrial tumor cells. Therefore, the investigators aim to determine the PIBF expression levels in the endometrial cancer cells.

Condition or disease
Progesterone Induced Blocking Factor in Endometrial Cancer

Detailed Description:
This retrospective controlled study will be conducted at both Obstetrics and Gynecology clinics and Pathology clinics of Kayseri Training and Research Hospital. This study will be conducted with the use of formalin fixed paraffin embedded tissue blocks immunohistochemically to determine the PIBF expression levels in the samples. There are three groups in this study; endometrial cancer, endometrial hyperplasia and normal endometrium and each of the groups contained 20 paraffin embedded blocks provided form the Pathology clinic of Kayseri Training and Research Hospital archives.

Layout table for study information
Study Type : Observational
Actual Enrollment : 60 participants
Observational Model: Case-Control
Time Perspective: Retrospective
Official Title: Determining Levels of Expression of Progesterone-Induced Blocking Factor in Endometrial Cancer Cells.
Actual Study Start Date : August 2016
Actual Primary Completion Date : December 2016
Actual Study Completion Date : March 2017

Resource links provided by the National Library of Medicine


Group/Cohort
study group1
20 paraffin embedded blocks which was diagnosed endometrial cancer
control group
20 paraffin embedded blocks of healthy women
study group2
20 paraffin embedded blocks which was diagnosed endometrial hyperplasia



Primary Outcome Measures :
  1. Immunohistochemically Levels of PIBF in Endometrial Cancer Cells [ Time Frame: 3 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
There are three groups in this study; endometrial cancer,endometrial hyperplasia and normal endometrium and each of the groups contained 20 paraffin embedded blocks provided from the Pathology clinic of Kayseri Training and Research Hospital archives.
Criteria

Inclusion Criteria:

  • diagnosed endometrial cancer
  • diagnosed endometrial hyperplasia

Exclusion Criteria:

  • diagnosed cancer except endometrial cancer
Layout table for additonal information
Responsible Party: Erdem Sahin, Director, Kayseri Education and Research Hospital
ClinicalTrials.gov Identifier: NCT02852954    
Other Study ID Numbers: 2016/405
First Posted: August 2, 2016    Key Record Dates
Last Update Posted: August 18, 2017
Last Verified: August 2016
Keywords provided by Erdem Sahin, Kayseri Education and Research Hospital:
Progesterone Induced Blocking Factor
Endometrial Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Endometrial Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Diseases
Genital Diseases, Female